Close Menu

NEW YORK — Quanterix took another step toward the diagnostics market last week with an agreement to license its high-sensitivity immunoassay technology to Abbott Laboratories.

The non-exclusive license allows Abbott to incorporate Quanterix's Simoa technology into its in vitro diagnostic platforms in exchange for an initial $10 million license fee, milestone fees subject to the achievement by Abbott of development, regulatory, and launch milestones, and royalties on the sales of licensed products.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.